|

CAR-T cells targeting CD19 and CD22 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

  • University Hospital Tuebingen1

Indications

  • CLL1
  • Acute Lymphoblastic Leukemia, Pediatric1
  • Lymphoma1
  • Cancer1

Other1 trial

A Phase I Dose Finding Study of MB-CART2219.1
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.